Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open‐label, single‐dose, parallel‐group study

AIMS: The study objective was to evaluate the pharmacokinetics of the selective progesterone receptor modulator vilaprisan in participants with hepatic impairment. Additionally, the safety and tolerability of vilaprisan were investigated. METHODS: In this phase 1, open‐label, nonrandomised, parallel...

Descripción completa

Detalles Bibliográficos
Autores principales: Chattopadhyay, Niladri, Riecke, Kai, Ligges, Sandra, Zimmermann, Torsten, Halabi, Atef, Schultze‐Mosgau, Marcus‐Hillert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710501/
https://www.ncbi.nlm.nih.gov/pubmed/31112623
http://dx.doi.org/10.1111/bcp.13992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710501/
https://www.ncbi.nlm.nih.gov/pubmed/31112623
http://dx.doi.org/10.1111/bcp.13992

Ejemplares similares